^Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). „MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”.International journal of immunopathology and pharmacology.18 (1): 21—31.PMID15698508.
^Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). „Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”.Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.5 (2): 107—17.PMID15204012.doi:10.1080/14660820410019602.